ICU Medical (ICUI) Q4 2012 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2012 earnings summary
6 Nov, 2026Executive summary
FY12 revenue rose 4.9% to a record $316.9M; growth in oncology, infusion therapy and TEGO offset the expected critical care decline.
Gross margin expanded 230 bps to 49.4%; net income was $41.3M, or $2.80 diluted EPS.
Debt-free year-end position included $226.2M in cash, cash equivalents and investment securities, with record operating cash flow of $66.3M.
Financial highlights
FY12 total revenue was $316.9M vs. $302.2M in FY11; net sales were $316.3M vs. $301.6M.
Operating income was $61.3M vs. $65.2M; net income was $41.3M vs. $44.7M.
Diluted EPS was $2.80 vs. $3.15; basic EPS was $2.90 vs. $3.23.
Gross profit increased to $156.5M from $142.4M; gross margin rose to 49.4% from 47.1%.
Operating cash flow reached $66.3M vs. $64.5M; cash and investments ended the year at $226.2M vs. $160.0M.
Outlook and guidance
FY13 U.S. Hospira sales were expected to be comparable to or slightly below FY12, with Q1 orders planned lower and normal levels expected in Q2–Q4.
FY13 outlook called for modest growth in other domestic, international and infusion therapy sales; significant oncology growth; and lower critical care sales.
FY13 SG&A and R&D were each expected at ~27% and ~3% of revenue, respectively; effective tax rate was expected at ~34%.
FY13 capital expenditures were estimated at $30M–$35M, mainly for Salt Lake City capacity expansion, manufacturing equipment and IT.
New product launches, expanded sales and marketing, R&D and possible acquisitions were identified as priorities for profitable growth.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020